Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Revelation Biosciences Inc (NQ: REVB ) 1.020 -0.040 (-3.77%) Streaming Delayed Price Updated: 11:17 AM EDT, Sep 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Revelation Biosciences Inc < Previous 1 2 3 4 5 6 7 8 9 10 Next > Nasdaq Down Over 200 Points; Williams-Sonoma Shares Tumble After Q2 Results August 22, 2024 Via Benzinga Gold Down Over 1%; US Initial Jobless Claims Increase August 22, 2024 Via Benzinga Dow Jumps 100 Points; BJ's Wholesale Earnings Top Estimates August 22, 2024 Via Benzinga Topics Stocks Exposures US Equities Why Wolfspeed Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket August 22, 2024 Via Benzinga Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds August 21, 2024 From Revelation Biosciences Inc. Via Business Wire US Stocks Higher; Target Posts Upbeat Earnings August 21, 2024 Via Benzinga Why Keysight Technologies Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket August 21, 2024 Via Benzinga Why Serve Robotics Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket August 14, 2024 Via Benzinga REVB Stock Earnings: Revelation Biosciences Misses EPS for Q2 2024 August 09, 2024 REVB stock results show that Revelation Biosciences missed analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024 August 09, 2024 From Revelation Biosciences, Inc. Via Business Wire Why Is Nano-Cap Revelation Biosciences Stock Skyrocketing On Monday? June 24, 2024 Revelation Biosciences reveals positive safety and biomarker data from its Phase 1 study (RVL-HV02) of Gemini. The study met its primary endpoint and identified a maximum tolerated dose. Via Benzinga Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity June 24, 2024 From Revelation Biosciences, Inc. Via Business Wire Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini June 13, 2024 From Revelation Biosciences, Inc. Via Business Wire 12 Health Care Stocks Moving In Friday's After-Market Session May 17, 2024 Via Benzinga REVB Stock Earnings: Revelation Biosciences Misses EPS for Q1 2024 May 10, 2024 REVB stock results show that Revelation Biosciences missed analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024 May 10, 2024 From Revelation Biosciences, Inc. Via Business Wire 12 Health Care Stocks Moving In Monday's Pre-Market Session April 22, 2024 Via Benzinga REVB Stock Earnings: Revelation Biosciences Beats EPS for Q4 2023 March 22, 2024 REVB stock results show that Revelation Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023. Via InvestorPlace Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023 March 22, 2024 From Revelation Biosciences, Inc. Via Business Wire 12 Health Care Stocks Moving In Thursday's After-Market Session March 14, 2024 Via Benzinga Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024) March 13, 2024 From Revelation Biosciences Inc. Via Business Wire Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference March 12, 2024 From Revelation Biosciences Inc. Via Business Wire Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini March 04, 2024 From Revelation Biosciences Inc. Via Business Wire Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) February 13, 2024 From Revelation Biosciences Inc. Via Business Wire Top 5 Health Care Stocks That Are Preparing To Pump In February February 09, 2024 The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. Via Benzinga BioMedNewsBreaks – Revelation Biosciences Inc. (NASDAQ: REVB) Secures ~$6.2M in Public Offering February 08, 2024 Via Investor Brand Network 12 Health Care Stocks Moving In Wednesday's After-Market Session February 07, 2024 Via Benzinga Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering February 05, 2024 From Revelation Biosciences Inc. Via Business Wire 12 Health Care Stocks Moving In Monday's After-Market Session February 05, 2024 Via Benzinga Why Skechers Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session February 02, 2024 Shares of Skechers U.S.A., Inc. (NYSE: SKX) shares fell during Friday’s session after the company reported mixed fourth-quarter financial results. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 10 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.